** Shares of medtech firm Glaukos Corp GKOS.N rise 3.3% to $158 premarket
** Brokerage Mizuho upgrades rating on GKOS to "outperform" from "neutral", citing its "disruptive potential" in the US glaucoma market
** Also raises PT to $200 from $140; representing a 30.8% upside to the stock's last close
** Brokerage says it believes iDose has a "substantial lead" in the drug-device combo setting and can drive up to $7 in adjusted EPS by 2030
** iDose is a device that helps lower eye pressure in people with glaucoma, a disease that damages the optic nerve, by slowly releasing medicine
** Expects iDose sales to reach over $1 bln by 2029, driven by a "favorable US adoption cycle with expanded coverage over the next several years"
** Says iDose has a unique advantage over competing products, such as Abbvie's ABBV.N Durysta implant, due to its "reservoir design that allows for continuous drug elution up to 3 years"
** GKOS gained 94.6% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。